• Explore /
  • Poster
  • / Cetuximab/irinotecan/5-FU +/-oxaliplatin or FOLFOXIRI +/- bevacizumab in patients with colorectal cancer and nonresectable liver metastases (AIO CELIM2-study).

Cetuximab/irinotecan/5-FU +/-oxaliplatin or FOLFOXIRI +/- bevacizumab in patients with colorectal cancer and nonresectable liver metastases (AIO CELIM2-study).

Abstract Video & Slides Poster

Authors

null

Gunnar Folprecht

University Hospital Carl Gustav Carus, Dresden, Germany

Gunnar Folprecht , Marika Mende , Torsten Liersch , Wolf Otto Bechstein , Claus-Henning Kohne , Alexander Stein , Volker Kunzmann , Michael Ghadimi , Ulf Peter Neumann , Sven Nilsson , Alexander Koenig , Ursula Pession , Achim Troja , Manfred Glados , Mathias Kleiss , Ulrike Ubbelohde , Juergen Weitz

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Session

Session Title

Gastrointestinal Cancer—Colorectal and Anal

Track

Gastrointestinal Cancer—Colorectal and Anal

Sub Track

Colorectal Cancer–Advanced Disease

Clinical Trial Registration Number

NCT01802645

Citation

J Clin Oncol 38: 2020 (suppl; abstr 4024)

DOI

10.1200/JCO.2020.38.15_suppl.4024

Abstract #

4024

Poster Bd #

16

Abstract Disclosures

Similar Posters

First Author: Akihito Tsuji

First Author: Hironaga Satake

First Author: Takanori Watanabe

First Author: Valerie Boige